fibromyalgia

Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.

The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.

The company is aiming to uncover the cause of fibromyalgia and to identify new disease-specific genetic biomarkers.

IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.

Biotech startup EpicGenetics last month launched its FM/A protein biomarker test for fibromyalgia with the aim of providing an objective method of diagnosing what has traditionally been a difficult to pin down disease.

Catalyst hopes to develop treatments for addiction and epilepsy based on the compounds, which may be more potent and induce fewer side effects than a related compound that Catalyst previously licensed from Brookhaven National Laboratory and is currently shepherding through clinical trials.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.